Dependence receptors (DRs) now form a family of more than a dozen membrane receptors that are not linked by their structure, but by common functional traits. The most notable is their ability to trigger two opposite signaling pathways: in the presence of ligand, these receptors activate classic signaling pathways implicated in cell survival, migration and differentiation. In the absence of ligand, they do not stay inactive, rather they elicit an apoptotic signal. Thus, cells expressing this kind of receptor are dependent on the presence of ligand in the extracellular environment to survive. This review will recapitulate the increasing data regarding the molecular mechanisms associated with DRs, their potential implication during development, as well as their deregulation during tumorigenesis and, finally, their emergence as new possible therapeutic targets for cancer treatment.
Dependence receptors (DRs) now form a family of more than a dozen membrane receptors that are not linked by their structure, but by common functional traits. The most notable is their ability to trigger two opposite signaling pathways: in the presence of ligand, these receptors activate classic signaling pathways implicated in cell survival, migration and differentiation. In the absence of ligand, they do not stay inactive, rather they elicit an apoptotic signal. Thus, cells expressing this kind of receptor are dependent on the presence of ligand in the extracellular environment to survive. This review will recapitulate the increasing data regarding the molecular mechanisms associated with DRs, their potential implication during development, as well as their deregulation during tumorigenesis and, finally, their emergence as new possible therapeutic targets for cancer treatment. Keywords: dependence receptors; apoptosis; caspase; tumor progression; cancer therapy Membrane receptors are classically considered as inactive unless bound to their ligand. However, increasing observations demonstrate that some receptors, in addition to their 'positive' signaling when their ligand is present, transduce a 'negative' signal that induces apoptosis in the absence of ligand (Figure 1 ). Cells expressing these receptors are thus dependent on the presence of ligand to survive. These receptors are named 'dependence receptors.' To date, the dependence receptor (DR) family is composed of more than a dozen members including DCC (deleted in colorectal carcinoma) (Mehlen et al., 1998) , UNC5Hs (uncoordinated 5 homologs), neogenin (Matsunaga et al., 2004) , p75 NTR (p75 neurotrophin receptor) (Rabizadeh et al., 1993) , RET (rearranged during transfection) (Bordeaux et al., 2000) , TrkC (tyrosine kinase receptor C) (Tauszig-Delamasure et al., 2007) , Ptc (patched) (Thibert et al., 2003) , EphA4 (ephrin type A receptor 4) (Furne et al., 2009) , ALK (anaplastic lymphoma kinase) (Mourali et al., 2006) , MET (Tulasne et al., 2004) and some integrins (Stupack et al., 2001) . All of them are involved in both nervous system development and cancer progression.
Dependence receptors: a short history

Neurotrophin receptor p75
NTR was the first DR to be described. P75 NTR was discovered as one of two receptors able to bind nerve growth factor (Chao et al., 1986) , the other being TrkA . TrkA was rapidly shown to mediate the known responses to NGF, such as neurite outgrowth and neuronal survival (Lee et al., 2001a; Lykissas et al., 2007) , whereas the precise biological role of p75 NTR remained misunderstood. p75
NTR was shown to collaborate with TrkA to form high-affinity sites for NGF binding (Hempstead et al., 1991) . In addition, p75 NTR was shown to alter the ligand specificity of other Trk receptors. For example, brain-derived neurotrophic factor, NT3 and NT4/5 can all bind TrkB in the absence of p75 NTR , whereas only brain-derived neurotrophic factor does so in the presence of p75 NTR . In contrast, coexpression of p75 NTR with TrkC results in a relaxation in its absolute specificity for NT3 (Hempstead, 2002) . At the time of its discovery, p75
NTR was considered as a unique type of protein but, subsequently, a large superfamily of tumor necrosis factor (TNF) receptors were found to share the overall structure of p75 NTR (Liepinsh et al., 1997) . Identification of this superfamily helped elucidate some of the biological functions of p75 NTR , including its link to cell death regulation. The relationship between these TNF death receptors, which induce cell death on binding of proapoptotic ligand such as TNF or FasL, and p75 NTR , which binds NGF, a trophic factor known to induce cell survival, led DE Bredesen and colleagues to propose that p75 NTR induces cell death when unoccupied by NGF, whereas binding of NGF blocks apoptosis (Rabizadeh et al., 1993) ( Figure 2 and Table 1 ). This finding suggested that p75 NTR expression creates a state of cellular dependence on NGF. Further studies with knockout mice confirmed this notion. First, p75 NTR -deficient mice have an increased number of cholinergic neurons, somal hypertrophy and hyperinnervation in some areas of the hippocampus (Yeo et al., 1997; Naumann et al., 2002) . In addition, crossing NGF hemizygous mice, which display a reduction in cholinergic cell numbers, with p75 NTR null mice showed that loss of p75 NTR partially restores cholinergic cell numbers (Naumann et al., 2002) . However, the overall picture of p75 NTR function became more complicated when some studies showed that p75 NTR induced apoptosis in response to ligand binding rather than ligand withdrawal (Casaccia-Bonnefil et al., 1996; Frade et al., 1996) . Particularly, in addition to its ability to bind mature neurotrophins, Figure 2 Representation of the DR family. The functional domains present in extra and intracellular domains are represented. DRs are not related to each other according to their structure, but according to their ability to induce apoptosis in the absence of ligand. All of them are caspase substrates, except p75NTR and integrins. The position of caspase cleavage sites is indicated. Localization of ADD, which has been more or less precisely determined depending on receptor, is indicated by double arrows. (Lee et al., 2001b) , b-amyloid (Yaar et al., 2002) and prion (Della-Bianca et al., 2001) peptides. The decision between ligandinduced apoptosis and ligand-inhibited apoptosis mediated by p75
NTR likely depends on cell type and development stage (Barrett and Bartlett, 1994) . Because the idea of a receptor triggering apoptosis when unbound to its ligand contradicted the dogma regarding receptor signaling and the trophic theory, considering p75 NTR as a classic death receptor had more success than considering it as a DR. Consequently, DR p75 NTR has been rather forgotten, although it was the first to be described and no definitive evidence has demonstrated that it is not a DR.
The concept reemerged with DCC. DCC was discovered in 1990 as a putative cell-surface receptor encoded by a gene frequently deleted through allelic loss in colorectal carcinoma (Fearon et al., 1990) . Observation that DCC expression is reduced or lost in colorectal cancer led to the proposal that DCC expression represented a constraint for disease progression and is therefore a tumor suppressor. This hypothesis was supported by the fact that DCC expression is lost or reduced in various cancers (Mehlen and Fearon, 2004) and that its loss of expression is associated with poor prognosis (Shibata et al., 1996; Sun et al., 1999) . In addition, restoration of DCC expression can suppress tumorigenic property in vitro and in nude mice (Klingelhutz et al., 1993; Velcich et al., 1999) . The DCC extracellular domain shares structural features with certain types of cell-adhesion molecules, such as NCAM (Cho et al., 1994) (Figure 2 and Table 1) , but its intracellular domain shows little similarity with known proteins; hence in spite of the above-mentioned studies on cancers, little was known about the precise biological role of DCC. It was rediscovered as the receptor for netrin-1 (Keino-Masu et al., 1996) , a diffusible molecule originally identified as a chemoattractant for commissural axons in the vertebral spinal cord (Serafini et al., 1994) . The classic view for netrin-1 is that a gradient of this cue diffuses from a ventral spinal cord structure, the floor plate, and orients the growth of commissural axons as they extend circumferentially toward the ventral midline of the embryonic nervous system. The key role of DCC and netrin-1 in mediating axon outgrowth and pathfinding is supported by a large number of studies, particularly the analysis of DCC and netrin-1 knockout mice, which display similar defects in the central nervous system (Serafini et al., 1996; Fazeli et al., 1997) . Such a dual role for a receptor, implicated during development and functioning as a putative tumor suppressor, seems to be a common trait for DRs. DCC was thus proposed as a DR when it was shown that its expression in various cancer cell lines that lacked endogenous DCC expression induced cell death and that addition of netrin-1 blocked apoptosis (Mehlen et al., 1998; Chen et al., 1999) .
Netrin-1 is in fact the founding member of a family of extracellular proteins found throughout the animal kingdom and that direct cell and axon migration during embryogenesis. In vertebrates, besides netrin-1, four other netrins have been described: netrin-2/3/2like, netrin-4/b, netrin-G1 and netrin-G2 (Puschel, 1999; Mehlen and Mazelin, 2003) . Netrins are structurally related to the short arm of laminin (g for netrin 1-3 and b for netrin-4, G1 and G2). Netrins 1-4 are secreted, whereas netrin-G1 and G2 are membrane anchored by means of a glycophosphatidylinol tail. Secreted netrins exert their biological functions by binding to receptors such as DCC, UNC5, neogenin and DSCAM, whereas netrin Gs do not interact with these receptors (Rajasekharan and Kennedy, 2009 ). Interestingly, netrin-5 has recently appeared in databases, which seems to be related to the netrin 1-3 group according to its sequence. Netrin-1 is the most studied member of the netrin family and to date it seems to be the main ligand for DCC, as well as for UNC5 receptors (see below), although a recent report mentioned that netrin-4 could interact with DCC and UNC5H1 (Qin et al., 2007) .
The UNC5 receptor was initially identified in Caenorhabditis elegans as an axonal guidance transmembrane receptor (Leung-Hagesteijn et al., 1992) and, on the basis of a genetic screen, was predicted to interact with UNC6 (the C. elegans netrin-1 ortholog) (Hedgecock et al., 1990) . Four homologs of UNC5 have been described in mammals (UNC5H1, 2, 3 and 4 in rodents and UNC5A, B, C and D in humans) (Leonardo et al., 1997) . Although DCC alone is implicated in the chemoattractive effect of netrin-1, it has been proposed that UNC5, associated with DCCs through their intracellular domains, is responsible for the repulsive effect of netrin-1 (Hong et al., 1999) . Besides this role, UNC5 receptors are now known to have critical roles in other cellular processes, such as neuronal migration (Mehlen and Furne, 2005) and embryonic angiogenesis (Lu et al., 2004) . Interestingly, UNC5 proteins contain a death domain related to the death domain of the TNF receptor superfamily in their cytoplasmic part. As UNC5 receptors were netrin-1 receptors and contained a death domain, it was suggested that they were possible DRs ( Figure 2 and Table 1 ). Along this line, UNC5 receptors are able to induce apoptosis in the absence of netrin-1, whereas addition of ligand efficiently blocked this effect (Llambi et al., 2001; Wang et al., 2008) .
A DCC homolog was discovered and called neogenin (Vielmetter et al., 1994; Meyerhardt et al., 1997) . Although there is only one member of the DCC receptor family in C. elegans and Drosophila (UNC40 and frazzled, respectively), vertebrates have evolved two closely related orthologs, DCC and neogenin. Owing to its identity of sequence with DCCs, especially in their ectodomain, neogenin was initially considered to be a netrin-1 receptor as well. However, more recently, the propensity of netrin-1 to function as a ligand for neogenin was challenged when neogenin seemed to have much higher affinity for RGM (repulsive guidance molecule), another guidance molecule, and to mediate its repulsive effect (Rajagopalan et al., 2004) . RGM was first identified as a repulsive, membrane-bound cue responsible for the mapping of temporal retinal axons to the posterior region of the chick tectum (Monnier et al., 2002) . In mammals, three RGMs exist: RGMa, the closest ortholog of chick RGM, RGMb/DRAGON and RGMc/hemojuvelin. RGMa and b are both expressed in the central nervous system and follow a complementary expression pattern (Niederkofler et al., 2004) , whereas RGMc is mainly expressed in striated muscles and liver (Schmidtmer and Engelkamp, 2004) . Neogenin is a DR in that it can induce apoptosis when overexpressed in chick neural tube, and its ligand, RGM, but not netrin-1, counteracts this process (Matsunaga et al., 2004) ( Figure 2 and Table 1 ). It should be noted that the question of neogenin's ligand remains tricky: despite its higher affinity for RGM, neogenin seems to be able to mediate netrin-1 signaling in axon attraction (Wilson and Key, 2006) or cell adhesion (Srinivasan et al., 2003) . Moreover, neogenin has also been proposed to mediate netrin-3 signaling during myotube formation (Kang et al., 2004) , as well as netrin-4 signaling in angiogenesis (Lejmi et al., 2008) .
Patched (Ptc) is a 12-transmembrane receptor that is part of the complex responsible for sonic hedgehog (Shh) morphogen signaling ( Figure 2 and Table 1 ). Shh binds Ptc and thus abolishes the Ptc-repressing effect on smoothened (Smo). Smo is a seven-transmembrane receptor that activates downstream Gli transcription factors (Murone et al., 1999) . Shh is a glycoprotein secreted by the notochord and floor plate during development, after a ventro-dorsal concentration gradient in the ventral neural tube. This gradient determines the induction and specification of ventral neurons in the vertebrate neural tube (Jessell, 2000) . In addition to its morphogen activity, Shh was also shown to be a survival factor: indeed, Le Douarin and colleagues discovered that experimental withdrawal of Shh in chick embryos by partial destruction of the notochord leads to massive cell death in the developing neural tube (Charrier et al., 1999 (Charrier et al., , 2001 . It was subsequently demonstrated that Shh functions as a survival factor by inhibiting the apoptotic function of Ptc (Thibert et al., 2003) . Thus, Ptc is a DR and can signal independently of Smo.
Integrins are the main receptors that mediate cellular interactions with extracellular matrix ligands such as laminins, collagens and fibronectins (Hood and Cheresh, 2002) . They are heterodimeric (ab) type I transmembrane receptors, and provide a connection between the matrix and the cytoskeleton. Integrins have traditionally been considered as prosurvival receptors, on the basis of the concept of 'anchorage dependence' (Stupack and Cheresh, 2002) . Integrin-mediated adhesion supports the formation of cytoskeletal and contractile elements, promotes cellular resistance to exogenous apoptotic stimuli and facilitates signaling by trophic factor receptors. Most cells require integrin-mediated adhesion to respond to trophic factors. This has led to the proposal that controlling cell adhesion and geometry, thereby permitting responsiveness to survival factors, may be the critical function of integrins in maintaining cell viability. However, expression of certain b3 or b1 integrins can also induce apoptosis, if immobilized substrates are not available as ligands.
These 'non-liganded integrins,' which are either unligated or occupied with a soluble antagonist, not only disrupt survival signaling but also actively induce apoptosis, hence supporting the view of integrins as DRs (Stupack et al., 2001) (Figure 2 and Table 1) .
Beside these receptors, some classical tyrosine kinase receptors have also emerged as DRs. RET was the first one ( Figure 2 and Table 1 ). RET is the signaling component of a multisubunit complex that functions as a receptor for glial cell line-derived neurotrophic factor (Jing et al., 1996) , neurturin, artemin and persephin (Kotzbauer et al., 1996) , four homologous neurotrophic factors related to the transforming growth factor-b family. The receptor complex also includes (GPI)-anchored proteins GFRa1, 2, 3 and 4 that are required for RET dimerization and dictate ligand selectivity (Baloh et al., 2000; Scott and Ibanez, 2001 ). After interaction with its ligands, RET undergoes autophosphorylation and then interacts with multiple effectors such as phospholipase C, Shc, enigma, Grb2, Grb7/ Grb10, Src kinase and Ras-GAP (Santoro et al., 1994; Arighi et al., 1997; Lorenzo et al., 1997) . Gainof-function mutations of the RET gene have been associated with multiple endocrine neoplasia type 2 (MEN 2), an autosomal dominant inherited cancer syndrome (Mulligan et al., 1993) , whereas loss-offunction mutations of RET have been associated with Hirschsprung disease (aganglionosis, HSCR), a frequent congenital intestinal malformation (1 in 5000 live births) characterized by the absence of neural crest-derived parasympathetic neurons of the hindgut (Edery et al., 1994; Romeo et al., 1994) . In vitro, MEN 2-associated mutations lead to ligand-independent constitutive activation of RET kinase activity either through covalent dimerization of the receptor (MEN 2A) (Santoro et al., 1995) or through direct structural changes in its kinase domains (MEN 2B) (Songyang et al., 1995) . In contrast, the mechanisms leading to the absence of intramural ganglion cells of the hindgut observed in HSCR remain incompletely understood. The observation that RET is involved in both cancer progression and nervous system development, similar to previously identified DRs, led to the question as to whether it could also be one of them. It was then shown that, in different settings, expression of RET induced apoptosis in the absence, but not in the presence, of glial cell line-derived neurotrophic factor (Bordeaux et al., 2000; Canibano et al., 2007) .
Trk receptors (TrkA, B and C) are the main neurotrophin receptors. TrkA is the receptor for NGF, TrkB is the receptor for brain-derived neurotrophic factor and NT4/5, whereas TrkC is the receptor for NT3 (Kaplan and Miller, 2000) . The classic neurotrophic theory proposes that neuronal survival depends on the presence of trophic factors such as neurotrophins (LeviMontalcini and Angeletti, 1963; Huang and Reichardt, 2001) , and that cell death, which occurs when these factors become limited, is strictly due to loss of survival signals. On neurotrophin binding, Trk receptors activate PI3K/Akt and Ras/MAP kinase pathways that are thought to inhibit the naturally occurring death program in neurons (Kaplan and Miller, 2000) . However, in light of what was known about DRs, it was tempting to hypothesize that neurotrophin binding served also to block an active apoptotic signal from Trks. Interestingly, when Trk receptors were evaluated as possible DRs, TrkC was the only one the enforced expression of which induced cell death in the absence of ligand (Tauszig-Delamasure et al., 2007) . Thus, TrkC is a DR, whereas TrkA and B are not, suggesting that even a closely related receptor can acquire a different activity with regard to cell survival and apoptosis ( Figure 2 and Table 1 ).
Anaplastic lymphoma kinase (ALK) tyrosine kinase is a member of the insulin receptor superfamily ( Figure 2 and Table 1 ). It was initially identified as part of the oncogenic nucleophosmin-ALK fusion protein resulting from the t(2;5) translocation that is frequently associated with anaplastic large-cell lymphoma (Morris et al., 1994) . Nucleophosmin allows dimerization of the fusion protein, causing constitutive activation of ALK kinase and downstream activation of phospholipase C-g, PI3K, STATs and pp60c-src (Allouche, 2007) . The native full-length ALK receptor is mainly expressed in discrete regions of the developing central and peripheral nervous system (Iwahara et al., 1997) . Mourali et al. (2006) forced ALK expression in cells of lymphoid and neuronal origin to investigate wild-type ALK functions. They observed that ALK enhanced or triggered apoptosis in these cells and that treatment with agonist antibodies mimicking ALK ligand prevented cell death induction (Mourali et al., 2006) .
Eph receptors constitute the largest family of tyrosine kinase receptors and bind ligands called ephrins ( Figure 2 and Table 1 ). Eph receptors regulate a diverse array of cellular processes during development, such as axon guidance, angiogenesis, or cell migration and positioning (Pasquale, 2005) . More recently, some ephrin and Eph receptors have been found to affect cell death in neurogenic regions. Activation of EphA7 by overexpressed ephrinA5 in the embryonic cortex resulted in neural progenitor apoptosis (Depaepe et al., 2005) . On the other hand, lack of ephrinB3 is associated with apoptosis in the subventricular zone of adult mice (Ricard et al., 2006) , suggesting that its receptor could function as a DR. EphA4 has been shown to function as a DR, the apoptotic activity of which is impaired by its ligand ephrinB3 (Furne et al., 2009) .
Another tyrosine kinase receptor should probably be added to the list: MET, the receptor for hepatocyte growth factor (Figure 2 and Table 1 ). MET is well known for its essential role in normal development and cell survival. Interestingly, it was reported that MET was cleaved under stress conditions by caspase, thereby generating an apoptotic fragment (Tulasne et al., 2004) . As we will see below, caspase cleavage is one of the most common traits for apoptotic signaling of DRs. Moreover, hepatocyte growth factor inhibits this caspase cleavage and concomitantly apoptosis. Therefore, although it is not clear whether MET is able to initiate apoptosis by itself in the absence of ligand, as other DRs do, this receptor presents some striking similarities with DRs.
To close this list, it should be mentioned that a nontransmembrane receptor, androgen receptor (AR), has also been proposed to be a DR (Ellerby et al., 1999) . AR is a member of the nuclear receptor superfamily of ligand-activated transcription factors. Binding of androgens such as testosterone by the AR leads to nuclear translocation and transcriptional activity. Gene regulation by the AR affects widespread processes such as male gonadal development, cell survival and muscular development, among many others (Lee and Chang, 2003) . AR displays a profile similar to that of membrane DRs; it is a caspase substrate and its expression induces apoptosis in the absence of ligand, whereas the addition of ligand inhibits receptor-induced cell death (Ellerby et al., 1999) . Mutations in the AR are associated with both prostate cancer and neurodegeneration. Neurodegeneration-associated mutants give rise to Kennedy's disease, a syndrome associated with the degeneration of motor neurons in the brainstem and spinal cord, resulting in weakness and muscular atrophy. Interestingly, mutations associated with neurodegeneration consist in expansion (430) of polyglutamine tracts present in the N-terminal part of the receptor, whereas shortened tracts (p22) are associated with a greater risk of developing prostate cancer (Nelson and Witte, 2002; Clark et al., 2003) . AR, similar to p75 NTR , has been quite forgotten as a DR. Paradoxically, the word 'dependence' is frequently associated with AR in the field of prostate cancer. Indeed, studies have led to the concept that prostate secretory epithelial cells require testosterone for survival, and the withdrawal of testosterone leads to apoptosis in these cells (Craft and Sawyers, 1998) . Thus, neoplastic prostate epithelial cells are often treated by hormone deprivation because it leads to apoptosis as a result of their dependence on testosterone. It is quite regrettable that no link has ever been made between the dependency phenomenon of prostate cancer cells and the fact that AR could behave as a DR.
DRs are caspase substrates
The molecular hallmark of programmed cell death (apoptosis) is the activation of caspases (Thornberry and Lazebnik, 1998) . During apoptosis, caspases, which form a family of cysteine-dependent aspartate-directed proteases, can cleave a wide range of substrates, thereby inactivating survival and activating proapoptotic mechanisms. Except for the fact that they induce apoptosis in the absence of their ligand, the other most common characteristic of DR is that they are cleaved by caspases. Receptor cleavage is important for apoptotic function, as mutation of the cleavage site abolishes cell death induction. DCC, neogenin, Ptc, ALK, EphA4 are cleaved once, roughly in the middle of their intracellular domain (Mehlen et al., 1998; Thibert et al., 2003; Matsunaga et al., 2004; Mourali et al., 2006; Furne et al., 2009) . The cleavage site of UNC5 receptors is very close to the plasma membrane (Llambi et al., 2001) , whereas RET, Trkc and MET have two cleavage sites A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen (Bordeaux et al., 2000; Foveau et al., 2007; TauszigDelamasure et al., 2007) . The cases of p75 NTR and integrins are less clear, as there is no solid evidence that caspase cleavage is needed for their proapoptotic effect. Interestingly, caspase cleavage sites of DRs seem to be conserved in mammals, variably in other vertebrates but never in orthologs in lower organisms, such as nematode or Drosophila (Table 2) (Mehlen and Thibert, 2004) . These findings may suggest that the appearance as a caspase substrate, and therefore the mediation of the dependence state, is a relatively late event in the evolution of these proteins. This may make sense, given the greater plasticity of the mammalian nervous system compared with those of invertebrates and the necessity for more complex and higher lifespan mammals to develop antitumor mechanisms.
Role of ligand binding
Another common feature of DRs is the inhibition of apoptosis induction on ligand binding. The main hypothesis with regard to the role of ligand binding is inhibition of the caspase cleavage. This hypothesis has been partly confirmed for some DRs, UNC5H2 (Tanikawa et al., 2003) , TrkC (Tauszig-Delamasure et al., 2007), EphA4 (Furne et al., 2009) and MET (Tulasne et al., 2004; Foveau et al., 2007) . For other receptors, the effect of ligand on caspase cleavage cannot be assessed because cleavage products have relatively short half-lives and are thus hardly detectable in vivo. On the other hand, ectopic expression of a truncated receptor, mimicking the caspase cleaved receptor, leads to apoptosis induction even in the presence of ligand (Mehlen et al., 1998; Thibert et al., 2003; Matsunaga et al., 2004) . This is an indirect argument in favor of a role for the ligand in caspase cleavage inhibition. In addition, ligand binding has been proposed to have other structural effects, such as receptor multimerization. In fact, with the exception of Ptc and integrins, most DRs display homo-multimerization properties in the presence of their respective ligand Manie et al., 2001; Stein et al., 2001; Mille et al., 2009a) . Initially described as being important for positive signaling, receptor multimerization also seems to have a role in blocking apoptosis induction. P75
NTR exerts its proapoptotic effect as a monomer, whereas multimerization abrogates this effect . In the same way, results obtained with DCC and UNC5H2 showed that these receptors trigger cell death when their ligand-induced multimerization is hindered (Mille et al., 2009a) . Netrin-1 has also been proposed to suppress the apoptotic function of UNC5H2 by inducing interaction of the receptor with the GTPase PIKE-L . This interaction triggers the activation of PI3 kinase signaling and consequently the inhibition of UNC5H2 proapoptotic function. Furthermore, recent data from cristallography evidenced that the UNC5H2 intracellular domain adopts an autoinhibited closed conformation. In this conformation, ZU5 and death domains bind to each other and are thus unable to induce cell death. Netrin-1 is unable to prevent apoptosis induced by the UNC5H2 mutant that has a constitutive open conformation, which leads the authors to suggest that netrin-1 somehow stabilizes the autoinhibited conformation of UNC5H2 (Wang et al., 2009) .
It must be noted that, for receptors accepting more than one ligand, the antiapoptotic effect has not been demonstrated for all ligands. For example, only glial cell line-derived neurotrophic factor was shown to block RET-induced apoptosis (Bordeaux et al., 2000) , no data are available for neurturin, artemin and persephin, although neurturin, similar to glial cell line-derived neurotrophic factor, was recently proposed to be a A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen survival factor for parasympathetic neurons (Peterziel et al., 2007) . In the case of neogenin, the ligand antiapoptotic effect was reported only for chick RGM/ RGMa (Matsunaga et al., 2004) but not for other members of the RGM family or for netrin-1/3/4. EphA4-associated cell death induction is hindered by ephrinB3, but not by its other known ligands, ephrinA1 and ephrinA4 (Furne et al., 2009) . With regard to ALK, only ligand-mimicking antibodies have been used because the identity of the receptor's physiological ligand is still a matter of debate. Pleiotrophin and midkine, two heparinbinding growth factors, have been proposed to function as ALK ligand but these proteins fail to make a general consensus. This controversy is further supported by the genetic identification in Drosophila melanogaster of an ALK ligand, jelly belly (jeb), which has no similarities with pleiotrophin or midkine Loren et al., 2003) . Finally, in the particular case of integrins, the ligand must be an immobilized substrate ligand to block apoptosis as, contrary to other DRs, soluble ligand is not sufficient to counteract cell death induction (Stupack, 2005) .
Proapoptotic signaling by DRs
DRs share the property of being caspase amplifiers; indeed most of them fail to induce apoptosis in the presence of general caspase inhibitors such as zVADfmk (Mehlen and Thibert, 2004) . The way that leads to caspase activation and amplification has begun to be decrypted specifically for some of them. First, all DRs contain, in their intracellular part, a domain required for apoptosis induction. This domain, the ADD (addiction/ dependence domain) , is required and often sufficient for cell death induction. Caspase cleavage, except for p75 NTR and integrins, is thought to be responsible for unmasking the ADD. In most cases, ADD is borne by the remaining membrane-anchored fragment. In the case of UNC5H, RET, TrkC and MET receptors, however, it is the cytosolic generated fragment that is proapoptotic. ADDs are usually unique regions that are not structurally related to known protein functional domains. Two notable exceptions are p75 NTR and UNC5H receptors: in those two cases, two regions corresponding to known functional domains are responsible for apoptosis induction. The first region is their death domain, which is structurally related to the death domain of receptors of the TNF receptor superfamily (Hofmann and Tschopp, 1995; Bredesen et al., 1998; Llambi et al., 2001) . The second region is the chopper domain for p75 NTR (Coulson et al., 2000) and the ZU5 domain for UNC5H (Williams et al., 2003) .
After ADD release/exposition, caspase amplification seems to be more or less direct, depending on receptors. In some cases, ADD recruits caspase-activating complexes that are different from those implicated in death receptors and in intrinsic mitochondrial classical apoptotic pathways. For example, in the absence of netrin-1, DCC recruits and activates caspase 9, thereby allowing caspase 3 activation, but this process does not require cytochrome c release and subsequent formation of an apoptosome (cytochrome c/apaf-1/caspase 9) complex, as is the case in the classic mitochondrial pathway (Forcet et al., 2001 ). DCC does not interact directly with caspase 9, hence it may recruit one or more adaptor proteins (Figure 3) . One of them could be DIP13a (DCC-interacting protein 13-a), a protein identified as an interactor of DCC ADD, and shown to be important for DCC-induced cell death (Liu et al., 2002) . However, the precise role of DIP13a in DCCtriggered apoptosis remains quite obscure, as it does not seem to mediate interaction of DCC with caspase 9 and further studies performed on DIP13a, also known as APPL1 (adaptor protein containing PH domain, PTB domain and leucine zipper motif 1), have not provided clear evidence for a role of this protein in apoptosis induction. In addition, palmitoylation and lipid raft localization were reported to be a prerequisite for DCC proapoptotic activity, both in vitro and in primary commissural neurons (Furne et al., 2006) . Lipid rafts are ordered membrane microdomains enriched in sphingolipids and cholesterol, and are proposed to have an important role in cell signaling, in particular through the organization of surface receptors, signaling enzymes and adaptor molecules into complexes at specific sites in the membrane (Simons and Toomre, 2000; Hueber, 2003) . It was then shown that DCC presence in lipid rafts is required to allow caspase-9/DCC interaction, suggesting that this caspase-activating complex occurs in and takes advantage of lipid rafts.
The discovery of a caspase-activating complex recruited to a DR was recently made for Patched. Ptc was indeed found to interact through its ADD, and only in the absence of its ligand Shh, with DRAL/FHL2 (Mille et al., 2009b) . DRAL was already known to promote apoptosis through an unknown mechanism in a wide variety of cells when overexpressed (Scholl et al., 2000) and to interact with TUCAN, a CARD-containing adaptor protein for caspases 1 and 9 (Stilo et al., 2002) . Mille and colleagues showed that the Ptc-DRAL association serves as a platform for recruiting TUCAN (and/or NALP1, a protein closely related to TUCAN) and caspase 9 (Figure 4 ). This then allows caspase 9 recruitment to Ptc and caspase 9 activation. The complex involving DRAL, TUCAN and caspase 9 was named dependosome, by analogy to other known caspase-activating complexes such as the apoptosome (comprising Apaf-1, cytochrome c and caspase 9), DISC (comprising Fas, FADD and caspase 8), the PIDDosome (comprising PIDD, RAID and caspase 2) and the inflammosome (comprising NALPs, ASC, caspases 1 and 5). Additional studies are required to determine whether this dependosome is a common platform for other DRs.
In any case, if such a dependosome existed and were common to DRs, the initiator recruited caspase could not always be caspase 9. Indeed, Stupack et al. (2001) elegantly showed that integrins, as DRs, trigger apoptosis through recruitment of caspase 8.
The formation of a caspase-activating complex does not seem to be the only mechanism used by DRs to trigger apoptosis. As an example, the mechanism of UNC5H-induced apoptosis has been documented. Despite their structural homology, members of the UNC5H family seem to mediate their apoptotic signal by interacting preferentially with distinct partners. In fact, apoptotic pathways downstream of UNC5H3 and 4 have not yet been documented, and functional data are available only for UNC5H1 and 2. UNC5H1 induces apoptosis by interacting with NRAGE (neurotrophin receptor-interacting MAGE homolog) through its ZU5 domain (Williams et al., 2003) . NRAGE possibly transduces UNC5H1-induced apoptosis through at least 
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Amplification of receptor cleavage
Caspase 3 activation Figure 3 Model of cell death induction by DCC. In the presence of netrin-1, DCC is dimerized and interacts with procaspase 3. Following ligand withdrawal, DCC becomes a monomer and is cleaved, possibly by bound caspase 3 or another activated protease. Cleavage leads to ADD exposure and to its direct interaction with apoptotic partners such as DIP13a, the role of which remains unclear, or to indirect interaction with caspase 9. Consequently, these interactions lead to caspase 9 activation, which in turn activates caspase 3.
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Caspase 3 activation Figure 4 Model of cell death induction by Ptc. Following ligand withdrawal, Ptc is cleaved by caspase (or by another activated protease), thus allowing exposure of its ADD. Ptc recruits DRAL, which in turns recruits TUCAN (or NALP1) and caspase 9. Formation of this complex leads to caspase 9 activation and consequently to caspase 3 activation.
A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen two pathways: one implicating the degradation of the caspase inhibitor XIAP, and the other implicating activation of the proapoptotic JNK signaling pathway. NRAGE can also interact with UNC5H2 and 3, but with a much weaker binding affinity. On the other hand, UNC5H2 triggers apoptosis mainly by recruiting the serine/threonine death-associated protein kinase (DAPK) (Llambi et al., 2005) . UNC5H2 and DAPK bind each other in part through their respective death domain, but not only so, as deletion of these domains is not sufficient to abrogate their association. Surprisingly, although UNC5H2-mediated induction of DAPK activity is observed only in the absence of netrin-1 and requires UNC5H2 caspase cleavage, DAPK seems to interact constitutively with UNC5H2, that is, not only in the absence of netrin-1. Indeed, DAPK is known to be capable of autophosphorylation, which inhibits its activity by inducing a conformational change (Shohat et al., 2001) . On this basis, and according to their observations, Llambi and colleagues proposed that, in the presence of netrin-1, DAPK is in an inactive autophosphorylated state, and it interacts with UNC5H2 through their non-'death domain'-interacting regions, whereas, in the absence of netrin-1, DAPK interacts with the death domain of UNC5H2, which allows DAPK activation ( Figure 5 ). This hypothesis strongly fits with the more recent study by Wang et al. (2009) , arguing that UNC5H2 can adopt a closed conformation, preventing association of the death domain with other proteins. Downstream effectors of DAPK in UNC5H2-mediated cell death remain to be identified, but DAPK is already known to trigger cell death through p53-dependent and -independent mechanisms. Moreover, phosphorylation of the myosin light chain by DAPK leads to membrane blebbing, a hallmark of programmed cell death (Gozuacik and Kimchi, 2006) . Interestingly, it was recently suggested that UNC5H2 was not the only DR to trigger apoptosis through DAPK, as neogenin was also shown to interact with DAPK and to require DAPK for apoptosis induction (Fujita et al., 2008) , in the same way that DCC, UNC5H1, 2 and 3 also require lipid raft association to induce cell death . Caspase 3 activation Apoptosis Figure 5 Model of cell death induction by UNC5H2/UNC5B. In the presence of netrin-1, UNC5H2 and UNC5B are dimerized, and their intracellular domain adopts a close conformation in which ZU5 and death domains interact with each other. DAPK interacts with the closed intracellular domain, but is in an inactive autophosphorylated state. Following ligand withdrawal, UNC5H2 receptor becomes a monomer, whereas the intracellular domain undergoes both caspase (or another protease) cleavage and opening/ dissociation of ZU5 and DD in parallel. Relation and chronology between cleavage and opening remain unclear, but these modifications should allow interaction between the DD of UNC5H and DAPK, thus leading to DAPK activation and initiation of an apoptotic program. Precisely how activated DAPK induces apoptosis remains to be determined.
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The fact that DRs are at the same time caspase substrates and caspase activators/amplifiers points out a paradox. How can a receptor that requires caspase cleavage to be a proapoptotic molecule participate in apoptosis induction? One possibility could be the initiation of DR cleavage by a noncaspase protease, which would be sufficient to generate a caspase amplification loop. Another view could be that caspases are never completely inactive, even in nonapoptotic cells, and that this residual caspase activity is sufficient to detect receptors disengaged from their ligand. Interestingly, caspase 3 was observed to interact with DCC, downstream of its cleavage site, only in nonapoptotic conditions, that is, in the presence of netrin-1, or when the DCC caspase cleavage site is mutated (Forcet et al., 2001) . It is tempting to speculate that, when dimerized in the presence of its ligand, DCC adopts a conformation that prevents its cleavage by caspases, whereas it can be efficiently cleaved as a monomer in the absence of ligand. This event results in unmasking its ADD, thus allowing capase 9 activation and caspase 3 amplification.
Role of DRs during embryonic development
Before being identified as DRs, all members of this functional family were already known to be implicated in nervous system development. Implications of their positive signaling in the presence of their ligand are largely documented, whereas a role for negative proapoptotic signaling long remained essentially speculative. However, several lines of evidence now accumulate to further support the view that DRs participate in nervous system development through their proapoptotic function as well. Because of this ability to trigger apoptosis in settings of ligand absence or limitation, they were hypothesized to control cell numbers in some specific areas of the developing brain and to dictate adequate territories of neuron migration and axon projection by eliminating those localized out of regions of ligand availability. For example, netrin-1 receptors do not only mediate the chemotropic effect of netrin-1 in the developing nervous system but also seem to regulate the survival of olivary neurons, as these cells, known to express DCC and UNC5H receptors, display increased apoptosis in netrin-1 À/À mice (Llambi et al., 2001 ). Moreover, netrin-1 functions as a survival factor for spinal cord commissural neurons, which was shown in both primary neuron cultures and animal models (Furne et al., 2008) .
Similarly, it was shown that Shh, the ligand of DR Ptc, is not only a morphogen but also a survival factor (Charrier et al., 1999 (Charrier et al., , 2001 . Interestingly, it was demonstrated that Shh functions as a survival factor by inhibiting the apoptotic function of Ptc and that this proapoptotic function is crucial for adequate neural tube development (Thibert et al., 2003; Mille et al., 2009b) .
The recent observation that neurotrophin receptor TrkC is a DR also led to questioning the implication of TrkC-induced apoptosis in the classic neurotrophin theory. The classic dogma suggests that each neuron is moving toward death unless a survival/neurotrophin signal is provided. The integration of the DR notion within this neurotrophin theory would then be that each neuron is actively pushed toward apoptosis by a DR, such as TrkC, in the context of ligand limitation, whereas ligand presence not only activates survival signals but also blocks the active process of cell death. The idea of TrkC being a DR is particularly attractive while analyzing data from knockout mice for neurotrophins and their respective receptors. Indeed, inactivation of TrkA or NGF in mice results in the same amount of sensory neuron loss at birth (that is, nociceptive neurons) (Crowley et al., 1994) . Similarly, inactivation of either TrkB or brain-derived neurotrophic factor results in an equivalent loss of mechanoceptive neurons (Ernfors et al., 1994; Minichiello et al., 1995) . On the other hand, neonates invalidated for TrkC present a loss of 30% DRG neurons, whereas NT-3 À/À neonates have lost 70% of them (Tessarollo et al., 1994 (Tessarollo et al., , 1997 . This is in agreement with the view that TrkC, contrary to TrkA and B, can trigger, when deprived of ligand, an active apoptotic signaling. A confirmation that TrkC apoptotic signaling controls the fate of sensory neurons is provided by an experience in which microinjection in sensory neurons of a mutated intracellular domain of TrkC, known to interfere with TrkC apoptotic function, dramatically enhanced survival of NT-3-deprived neurons (Tauszig-Delamasure et al., 2007) .
The ligand/DR pair ephrinB3/EphA4 was also recently demonstrated, by studying knockout mice, to have an important role in regulating cell number in an adult mouse subventricular zone through apoptosis modulation. Indeed, extinction of eprhinB3 results in increased apoptosis in subventricular zone, whereas the absence of EphA4 results in an excessive number of neuroblasts in this zone (Furne et al., 2009) . In addition, infusion of soluble ephrinB3 into the lateral ventricle reduced cell death. Thus, it is tempting to speculate that EphA4, as a DR, is important in regulating the fate of neuronal stem cells during brain development.
An elegant study from Palmer and colleagues evidenced a role for the ALK/jeb pair in the Drosophila-developing visual system. ALK is expressed and required in target neurons in the optic lobe, whereas jeb is primarily generated by photoreceptor axons and functions in the eye to control target selection of specific photoreceptor cell axons. Interestingly, the level of neuronal cell death (measured by active caspase 3 level) in the ALK expressing optic lobe medulla increases in mutants lacking an expression of jeb. Moreover, caspase-dependent neuronal apoptosis dramatically decreases in mutants overexpressing jeb (Bazigou et al., 2007) . These results suggest that ALK could have a role in the physiological negative selection of neurons shaping the optic lobe in the Drosophila nervous system by favoring apoptosis in the absence of the ALK ligand.
Interestingly, even though the data reported so far on the role of DRs during development seem to be linked to nervous system development, it has recently been proposed that these DRs may also be involved outside the developing nervous system. Along this line, netrin-1 was recently shown to control the survival of endothelial cells and to promote angiogenesis, at least in part, by blocking apoptosis triggered by its unbound UNC5H2 receptor (Castets et al., 2009) . The DR activity of UNC5H2 can indeed conciliate conflicting results regarding the implication of netrin-1 in angiogenesis (Lu et al., 2004; .
DRs are altered during tumor progression
In addition to a role during embryonic development, the DR model also predicts a role for such receptors as tumor suppressors, because of their ability to promote cell death when disengaged from their ligand. A tumor cell submitted to an abnormal environment (highly proliferative cells in an environment with limited and constant ligand concentration or metastatic cells migrating to sites in which ligand is absent) would display unbound DRs and thus undergo apoptosis (Figure 6 ). This mechanism would represent an alternative safeguard mechanism to limit tumor progression. It is then expected that in aggressive tumors, tumor cells have to turndown this DR pathway. Consistent with this view, a loss of receptor expression would then represent a selective advantage for tumor cells and seem to be a primary method to overcome this safeguard mechanism.
Since its discovery in the 1990s, DCC has been suspected to be a tumor suppressor gene, even though no definitive evidence has been proposed so far. Located on chromosome 18q, DCC is submitted to loss of heterozygosity in over 70% of colorectal cancers (Fearon et al., 1990) . DCC is also submitted to loss of heterozygosity and/or to decreased expression in various other cancers including gastric, prostate, endometrial, ovarian, esophageal, breast and testicular cancer, as well as neuroblastoma and hematological malignancies (Mehlen and Fearon, 2004) . Loss of DCC expression is often associated with poor prognosis and advanced cancer or metastasis (Shibata et al., 1996; Saito et al., 1999) , suggesting a role of DCC loss in cancer progression rather than in cancer initiation. Moreover, restoration of DCC expression can suppress tumorigenic growth properties in vitro or in nude mice (Klingelhutz et al., 1993; Velcich et al., 1999; Kato et al., 2000; Rodrigues et al., 2007) . On the other hand, the fact that only 10-15% of colon cancers carry mutations in DCC and the lack of a tumor predisposing effect of DCC inactivation in mouse models (Fazeli et al., 1997) led some investigators to conclude that DCC had little or no biological role in colon cancer, and that its inactivation was an epiphenomenon. However, such a categoric judgment was partly due to the lack of understanding of the biological roles of DCC, which has since been compensated by its characterization as a DR (Grady, 2007) .
In the same way, the UNC5H receptor family is downregulated in human cancers, including colorectal, breast, ovary, uterus, stomach, lung or kidney cancers (Thiebault et al., 2003) . Recently, two studies have focused on UNC5H3/UNC5C alteration in colorectal carcinoma. UNC5C is indeed the most downregulated member of the UNC5H family (74-77% of cases, A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen whereas UNC5H1/UNC5A and H2/B show a reduced expression in 48 and 27% of the cases, respectively). This loss of expression observed in human primary tumors, as well as in cell lines, is essentially due to promoter methylation (Bernet et al., 2007; Shin et al., 2007) . Furthermore, Bernet and colleagues took advantage of a natural UNC5H3 loss-of-function occurring in mice (rcm, rostral cerebellar malformation) to demonstrate that UNC5H3 loss of function is associated with tumor progression: mice that carry the APC 1638N germline mutation, known to predispose mice to the development of low-grade adenoma (Sieber et al., 2000) , and are heterozygous or homozygous for mutant UNC5H3, develop adenomas that progress to adenocarcinoma at a higher frequency than what is seen in APC 1638N mice. Interestingly, loss of UNC5H3 function in mice also correlates with apoptosis reduction in mice tumors. Another clue in favor of a role of the UNC5H family in cancer is that UNC5B and D are p53 target genes, able to mediate part of p53 proapoptotic activity (Tanikawa et al., 2003; Wang et al., 2008) .
Patched is also a known tumor suppressor (Stone et al., 1996) . Inactive mutations of Ptc, as well as loss of expression, are found in basal cell carcinoma and medulloblastoma (Wicking and McGlinn, 2001) . Ptc expression inhibits the hallmarks of cell transformation in vitro (Koike et al., 2002) and, interestingly, Ptc also inhibits growth in soft agar of transformed cells. This is linked to its proapoptotic function, as growth inhibition does not occur in the presence of Shh, or of a general caspase inhibitor, or when Ptc is mutated on its caspase cleavage site (Thibert et al., 2003) . However, there is no strong in vivo evidence so far that Ptc functions as a tumor suppressor because it triggers apoptosis.
There is a wide spectrum of data supporting the role of most DRs as tumor suppressors. As an example, EphA4 is downregulated in invasive forms of breast cancers (Fox and Kandpal, 2004) , in liver and kidney cancers (Hafner et al., 2004) and in metastatic melanomas (Easty et al., 1997) , whereas a progressive decrease in p75 NTR expression is described in prostate cancers (Pflug and Djakiew, 1998) . TrkC is associated with good prognosis in several cancers (Yamashiro et al., 1997) . However, the tumor suppressive functions of these receptors are yet to be demonstrated per se.
Whereas DR loss during tumorigenesis occurs in a wide fraction of cancers, another selective advantage for tumor cells would be to constitutively overexpress ligand. There is now accumulating evidence with regard to netrin-1 to support this idea. Indeed, forced expression of netrin-1 in the digestive tract of transgenic mice has been associated with decreased apoptosis in the intestine, development of advanced adenomas and tumor progression to adenomacarcinoma in a setting of adenoma predisposition (Mazelin et al., 2004) . More recently, high levels of netrin-1 were detected in a large panel of human cancers from distinct organs, and netrin-1 overexpression was correlated with a blocking of the proapoptotic functions of netrin-1 receptors. First, in breast cancer, netrin-1 was shown to be a marker of metastatic disease: decrease in netrin-1 expression by small interfering RNA or netrin-1 titration by decoy soluble receptor ectodomain causes apoptosis and prevents metastasis formation both in a syngenic mouse model and in a xenograft model (Fitamant et al., 2008) . In the same way, high levels of netrin-1 were detected in almost 50% of non-small-cell lung cancer and in a large fraction of aggressive neuroblastoma. As in the breast cancer study, strategies disrupting the netrin-1 autocrine loop led to apoptosis induction and tumor growth inhibition in xenografted models (Delloye-Bourgeois et al., 2009a, b) . In these three cases, apoptosis resulting from netrin-1 inhibition seems to be mediated by UNC5H receptors, rather than by DCC. Interestingly, in the case of aggressive neuroblastomas, netrin-1 expression levels were found to have prognosis significance. Aggressive stage 4 metastatic neuroblastoma is divided into three groups: stage 4 in children aged more than 1 year has the worse prognosis, whereas stage 4S and stage 4 in children less than 1-year old generally have a more favorable prognosis, even though many infants succumb to disease. High levels of netrin-1 were shown to correlate with adverse outcome of stage 4S and stage 4 (o1 year). A study by Link et al. (2007) , reporting that netrin-1 expression has significant impact on the overall survival of patients with poorly differentiated pancreas tumors, completes this description of netrin-1 upregulation in human neoplasias. Although the mechanism for autocrine production of netrin-1 remains to be determined, it could be at least in part a result of nuclear factor-kB activation, as netrin-1 is a direct target gene of this transcription factor . Moreover, according to the well-admitted link between inflammation and colorectal cancer predisposition, it has been suggested that nuclear factor-kB activation resulting from inflammatory stimulus could lead to local netrin-1 production, and thus to tumor promotion by apoptosis inhibition. Along this line, colorectal tumor formation in an animal model for chronic inflammation was inhibited by treatment with netrin-1 titrating agents (Paradisi et al., 2009 ).
Finally, a third possible way for tumor cells to escape the proapoptotic activity of DRs would be to inactivate their downstream signaling pathways. Notably, three effectors of DRs display functional inactivation in human cancers: DAPK, DRAL and caspase 8, which transduce UNC5H2-, Ptc-and integrin-mediated apoptosis, respectively. DAPK loss of expression, essentially through promoter methylation, has now been described in a wide variety of cancers, including lymphoma, leukemia, brain tumors, bladder, breast, renal, cervix, prostate and colorectal carcinomas (Kissil et al., 1997; Raveh and Kimchi, 2001; Gozuacik and Kimchi, 2006) . Moreover, DAPK loss of expression is associated with a more malignant tumor phenotype and increased metastatic capacity. DAPK is absent in highly metastatic variants of mouse lung cancer cell lines, and is present in the low metastatic variants of those same cell lines (Inbal et al., 1997) . In lung and head and neck cancers, DAPK promoter methylation was associated with aggressive disease and poor survival (Sanchez-Cespedes A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen et al., 2000; Tang et al., 2000; Kim et al., 2001; Kong et al., 2005) . DRAL was initially characterized as a downregulated gene in rhabdomyosarcoma (Genini et al., 1997) . Low or no transcript levels were observed in lymphoblastic leukemia, promyelocytic leukemia and Burkitt's lymphoma cells (Johannessen et al., 2006; Desmond et al., 2007) . Finally, caspase 8 expression is selectively lost during establishment of neuroblastoma metastases, rendering these cells refractory to unligated integrin-mediated cell death (Stupack et al., 2006) .
DRs as new therapeutic targets
Reactivating proapoptotic pathways in human cancer cells is one of the main strategies that is being developed in oncology nowadays. Therefore, DRs can join the list of promising targets for cancer treatment. Whereas restoring the expression of an extinguished receptorcoding gene does not seem conceivable, interfering with ligand binding seems to be a more pertinent approach, further supported by recent studies reporting an overexpression of netrin-1 in various cancers (Link et al., 2007; Fitamant et al., 2008; Delloye-Bourgeois et al., 2009a, b) . These studies provide an idea of what the future therapeutic molecules used in clinical studies could be; for example, a decoy receptor corresponding to the entire ectodomain of DCC receptor that would titrate the ligand, thus leading to unbound membrane receptors (Fitamant et al., 2008) . However, the large size (1100 aa) of the complete extracellular domain of DCC may complicate its use in vivo. An alternative could be to use shorter polypeptides, corresponding to the fourth or fifth fibronectin-like domain of DCC (Fitamant et al., 2008; Delloye-Bourgeois et al., 2009a, b) , which are both known to interact with netrin-1 (Geisbrecht et al., 2003) . Unlike the complete ectodomain, the fifth and fourth fibronectin-like domains do not counteract interaction between netrin-1 and its receptors, but rather block receptor multimerization (Mille et al., 2009a) . Alternatively, other interfering molecules, such as blocking antibodies or peptidomimetic compounds, could block the interaction between netrin-1 and its receptors. Interestingly, cancers that show high levels of netrin-1, that is, metastatic breast cancers, neuroblastoma, nonsmall-cell lung cancer and pancreatic cancers, are all tumors in which there is a need for effective new therapies. Moreover, and importantly, therapy resistance in cancer is frequently associated with deregulation in the mechanisms that control apoptosis, and cancer cells are often reliant on these molecular aberrations for survival. Inducing a novel apoptosis pathway may add one new component to the combined treatment of cancer, thereby increasing the therapeutic window. However, it remains to be determined whether interfering with DR/ligand pairs will stand the test of clinical tests. The situation in human patients is often more complex than that in murine experimental systems, and potential secondary effects due to perturbation of netrin-1 in normal tissues need to be evaluated. Finally, this therapeutic approach could be extended to other DR ligands besides netrin-1, if further investigations show abnormal expression levels in cancers.
Future members of the family?
The list of DRs is of course not closed, and future studies will probably reveal the unexpected ability of some receptors to induce apoptosis in the absence of ligand. Some receptors already share some intriguing characteristics with DRs. For example, ErbB2, a receptor tyrosine kinase related to the EGF receptor family, can be cleaved by caspase, and the generated cytosolic fragment triggers apoptosis (Tikhomirov et al., 2005; Strohecker et al., 2008) . Interestingly, this fragment contains a BH3-like domain related to the Bcl protein family involved in mitochondrial apoptosis. An important issue would be to check whether ErbB2 cleavage is affected by the presence of ligand. Unfortunately, ErbB2 remains, to date, an orphan receptor. The epidermal growth factor receptor and Notch1 receptors are also caspase substrates, but no effect of ligand binding has been reported, and caspase cleavage has only been proposed as a mechanism for turning down signaling by these receptors (He et al., 2003 (He et al., , 2006 Cohen et al., 2005 ). An even more promising candidate is the b-amyloid precursor protein (APP), a transmembrane receptor, the biological function of which remains largely unknown. APP abnormal processing by secretase proteases led to accumulation and extracellular deposit of the small Ab peptide associated with the development of Alzheimer's disease, a common neurodegenerative disorder (Koo, 2002) . Until recently, APP was an orphan receptor, yet it was recently proposed as a netrin-1 receptor (Lourenco et al., 2009 ). In addition, APP is known to be cleaved in its intracellular domain by caspase, thus yielding a toxic fragment (Nguyen et al., 2008) . Whether APP is a netrin-1 DR remains an intriguing question. In addition, if APP is a DR, one would expect it to function as a tumor suppressor. So far, no convincing data link APP to cancer, but this remains to be carefully assessed.
